Notice of Meeting of Chronic Hazard Advisory Panel on Phthalates and Phthalate Substitutes and Opportunity for Public Comment, 31426-31428 [2010-13389]
Download as PDF
<![CDATA[
31426
Federal Register / Vol. 75, No. 106 / Thursday, June 3, 2010 / Notices
Dated: May 24, 2010.
Ronald K. Lorentzen,
Deputy Assistant Secretary for Import
Administration.
Administrative Reviews and Request for
Revocation in Part, 75 FR 15679 (March
30, 2010).
On May 14, 2010, Monterey
Mushrooms, Inc. timely withdrew its
request for review.
[FR Doc. 2010–13373 Filed 6–2–10; 8:45 am]
BILLING CODE 3510–DS–S
DEPARTMENT OF COMMERCE
International Trade Administration
(A–560–802)
Certain Preserved Mushrooms from
Indonesia: Notice of Rescission of
Antidumping Duty Administrative
Review
AGENCY: Import Administration,
International Trade Administration,
Department of Commerce.
FOR FURTHER INFORMATION CONTACT:
David Goldberger or Kate Johnson,
Import Administration, International
Trade Administration, U.S. Department
of Commerce, 14th Street and
Constitution Avenue, N.W.,
Washington, D.C. 20230; telephone:
(202) 482–4136 or (202) 482–4929,
respectively.
SUPPLEMENTARY INFORMATION:
sroberts on DSKD5P82C1PROD with NOTICES
Background
On February 1, 2010, the Department
of Commerce (the Department)
published in the Federal Register a
notice of ‘‘Opportunity to Request
Administrative Review’’ of the
antidumping duty order on certain
preserved mushrooms from Indonesia
for the period of review (POR), February
1, 2009, through January 31, 2010. See
Antidumping or Countervailing Duty
Order, Finding, or Suspended
Investigation; Opportunity to Request
Administrative Review, 75 FR 5037
(February 1, 2010).
On March 1, 2010, in accordance with
19 CFR 351.213(b), the Department
received a timely request from Monterey
Mushrooms, Inc., a petitioner and a
domestic interested party in the above–
referenced proceeding, to conduct an
administrative review of the sales of PT
Eka Timur Raya (ETIRA), PT Indo
Evergreen Agro Business Corp., PT
Karya Kompos Bagas, and Tuwuh
Agung PT. Monterey Mushrooms, Inc.
was the only party to request this
administrative review.
On March 30, 2010, the Department
published in the Federal Register a
notice of initiation of an administrative
review of the antidumping duty order
on certain preserved mushrooms from
Indonesia with respect to these
companies. See Initiation of
Antidumping and Countervailing Duty
VerDate Mar<15>2010
18:21 Jun 02, 2010
Jkt 220001
Rescission of Administrative Review
Pursuant to 19 CFR 351.213(d)(1), the
Department will rescind an
administrative review, in whole or in
part, if the parties that requested a
review withdraw the request within 90
days of the date of publication of notice
of initiation of the requested review.
Monterey Mushrooms, Inc. withdrew its
request for review before the 90-day
deadline, and no other party requested
an administrative review of the
antidumping duty order on certain
preserved mushrooms from Indonesia.
Therefore, in response to Monterey
Mushrooms, Inc.’s withdrawal of its
request for review, and pursuant to 19
CFR 351.213(d)(1), the Department is
rescinding the administrative review of
the antidumping duty order on certain
preserved mushrooms from Indonesia
for the period February 1, 2009, through
January 31, 2010.
Assessment
The Department will instruct U.S.
Customs and Border Protection (CBP) to
assess antidumping duties on all
appropriate entries. Antidumping duties
shall be assessed at rates equal to the
cash deposit of estimated antidumping
duties required at the time of entry, or
withdrawal from warehouse, for
consumption, in accordance with 19
CFR 351.212(c)(1)(i). The Department
intends to issue appropriate assessment
instructions directly to CBP 15 days
after the date of publication of this
notice in the Federal Register.
Notification to Importers
This notice serves as a final reminder
to importers of their responsibility,
under 19 CFR 351.402(f)(2), to file a
certificate regarding the reimbursement
of antidumping duties prior to
liquidation of the relevant entries
during this review period. Failure to
comply with this requirement could
result in the Secretary’s presumption
that reimbursement of antidumping
duties occurred and the subsequent
assessment of double antidumping
duties.
Notification Regarding Administrative
Protective Order
This notice serves as the only
reminder to parties subject to
administrative protective order (APO) of
their responsibility concerning the
disposition of proprietary information
PO 00000
Frm 00015
Fmt 4703
Sfmt 4703
disclosed under APO in accordance
with 19 CFR 351.305(a)(3). Timely
written notification of return/
destruction of APO materials or
conversion to judicial protective order is
hereby requested. Failure to comply
with the regulations and the terms of an
APO is a sanctionable violation.
This notice is published in
accordance with section 777(i)(1) of the
Tariff Act of 1930, as amended, and 19
CFR 351.213(d)(4).
Dated: May 27, 2010.
John M. Andersen,
Acting Deputy Assistant Secretary for
Antidumping and Countervailing Duty
Operations.
[FR Doc. 2010–13436 Filed 6–2–10; 8:45 am]
BILLING CODE 3510–DS–S
COMMISSION OF FINE ARTS
Notice of Meeting
Established By Congress May 17, 1910.
The next meeting of the U.S.
Commission of Fine Arts is scheduled
for 17 June 2010, at 10 a.m. in the
Commission offices at the National
Building Museum, Suite 312, Judiciary
Square, 401 F Street, NW., Washington
DC, 20001–2728. Items of discussion
may include buildings, parks and
memorials.
Draft agendas and additional
information regarding the Commission
are available on our Web site: https://
www.cfa.gov. Inquiries regarding the
agenda and requests to submit written
or oral statements should be addressed
to Thomas Luebke, Secretary, U.S.
Commission of Fine Arts, at the above
address; by e-mailing staff@cfa.gov; or
by calling 202–504–2200. Individuals
requiring sign language interpretation
for the hearing impaired should contact
the Secretary at least 10 days before the
meeting date.
Dated: May 26, 2010 in Washington DC.
Thomas Luebke,
AIA Secretary.
[FR Doc. 2010–13176 Filed 6–2–10; 8:45 am]
BILLING CODE 6330–01–M
CONSUMER PRODUCT SAFETY
COMMISSION
Notice of Meeting of Chronic Hazard
Advisory Panel on Phthalates and
Phthalate Substitutes and Opportunity
for Public Comment
AGENCY: Consumer Product Safety
Commission.
ACTION: Notice of meeting.
E:\FR\FM\03JNN1.SGM
03JNN1
sroberts on DSKD5P82C1PROD with NOTICES
Federal Register / Vol. 75, No. 106 / Thursday, June 3, 2010 / Notices
SUMMARY: The Consumer Product Safety
Commission (‘‘CPSC’’ or ‘‘Commission’’)
announces the second meeting of the
Chronic Hazard Advisory Panel (CHAP)
on phthalates and phthalate substitutes.
The Commission appointed this CHAP
to study the effects on children’s health
of all phthalates and phthalate
alternatives as used in children’s toys
and child care articles, pursuant to
section 108 of the Consumer Product
Safety Improvement Act of 2008
(CPSIA) (Pub. L. 110–314). The public
may submit written or oral comments
on the issues to be considered by the
CHAP.
DATES: The opportunity to present oral
comments will be on July 26, 2010, from
10 a.m. to 5 p.m. The remainder of the
meeting will be from 8:30 a.m. to 5 p.m.
on July 27 and from 8:30 a.m. to 4 p.m.
on July 28, 2010. Requests to present
oral comments must be filed with the
Office of the Secretary no later than July
1, 2010. Written comments, and a
written copy of the text of the oral
comments, must be received no later
than July 12, 2010. Commenters should
limit their presentations to
approximately 15 minutes, exclusive of
any periods of questioning by the
members of the CHAP or the Consumer
Product Safety Commission (CPSC)
staff. The CHAP may further limit the
time for any presentation and to impose
restrictions to avoid excessive
duplication of presentations.
ADDRESSES: The meeting will be in the
fourth floor hearing room on July 26 and
27 and in room 410 on July 28, 2010, in
the Commission’s offices at 4330 East
West Highway, Bethesda, Maryland.
Written comments, or requests to
present oral comments and the written
text of such comments, should be
captioned ‘‘CHAP on Phthalates’’ and
sent by electronic mail (e-mail) to cpscos@cpsc.gov, or mailed or delivered to
the Office of the Secretary, Consumer
Product Safety Commission, 4330 EastWest Highway, Bethesda, Maryland
20814.
Online Registration and Webcast:
Members of the public who wish to
attend the meeting are requested to
preregister online at https://
www.cpsc.gov/cgibin/chap.aspx. This
meeting will also be available live via
webcast on July 26 and July 27, and by
prerecorded webcast on July 28, 2010, at
https://www.cpsc.gov/webcast.
Registration is not necessary to view the
webcast.
FOR FURTHER INFORMATION CONTACT:
Concerning requests and procedures for
oral presentations of comments:
Rockelle Hammond, Consumer Product
Safety Commission, Bethesda, MD
VerDate Mar<15>2010
18:21 Jun 02, 2010
Jkt 220001
20814; telephone: (301) 504–6833; email cpscos@cpsc.gov. For all other
matters: Michael Babich, Directorate for
Health Sciences, Consumer Product
Safety Commission, Bethesda, MD
20814; telephone (301) 504–07253; email mbabich@cpsc.gov.
SUPPLEMENTARY INFORMATION: The
Commission has previously investigated
potential risks posed to children from
phthalate plasticizers, especially di (2ethylhexyl) phthalate (DEHP) and
diisononyl phthalate (DINP), which
were used to soften some children’s
teethers, rattles, and toys made from
polyvinyl chloride (PVC). Phthalates
can leach from such products when they
are mouthed by children, causing some
phthalates to be ingested. In addition,
children and adults can be exposed to
phthalates from many sources,
including consumer products, food,
cosmetics, medical devices, and the
environment. Certain phthalates have
been shown to cause adverse health
effects, including birth defects, in
laboratory animals. Section 108 of the
CPSIA permanently prohibits the sale of
any ‘‘children’s toy or child care article’’
containing more than 0.1 percent of
each of three specified phthalates—di(2-ethylhexyl) phthalate (DEHP), dibutyl
phthalate (DBP), and benzyl butyl
phthalate (BBP). Section 108 of the
CPSIA also prohibits on an interim basis
the sale of any ‘‘children’s toy that can
be placed in a child’s mouth’’ or ‘‘child
care articles’’ containing more than 0.1
percent of each of three additional
phthalates—diisononyl phthalate
(DINP), diisodecyl phthalate (DIDP), and
di-n-octyl phthalate (DnOP).
Section 108 of the CPSIA requires the
Commission to convene a CHAP ‘‘to
study the effects on children’s health of
all phthalates and phthalate alternatives
as used in children’s toys and child care
articles.’’ The CPSIA requires the CHAP
to complete an examination of the full
range of phthalates that are used in
products for children and to: (i)
Examine all of the potential health
effects (including endocrine disrupting
effects) of the full range of phthalates;
(ii) consider the potential health effects
of each of these phthalates both in
isolation and in combination with other
phthalates; (iii) examine the likely
levels of children’s, pregnant women’s,
and others’ exposure to phthalates,
based on a reasonable estimation of
normal and foreseeable use and abuse of
such products; (iv) consider the
cumulative effect of total exposure to
phthalates, both from children’s
products and from other sources, such
as personal care products; (v) review all
relevant data, including the most recent,
PO 00000
Frm 00016
Fmt 4703
Sfmt 4703
31427
best-available, peer-reviewed, scientific
studies of these phthalates and
phthalate alternatives that employ
objective data collection practices or
employ other objective methods; (vi)
consider the health effects of phthalates
not only from ingestion but also as a
result of dermal, hand-to-mouth, or
other exposure; (vii) consider the level
at which there is a reasonable certainty
of no harm to children, pregnant
women, or other susceptible individuals
and their offspring, considering the best
available science, and using sufficient
safety factors to account for
uncertainties regarding exposure and
susceptibility of children, pregnant
women, and other potentially
susceptible individuals; and (viii)
consider possible similar health effects
of phthalate alternatives used in
children’s toys and child care articles.
The CHAP’s examination must be
conducted de novo, and the statute
specifies completion of its examination
within 18 months of appointment of the
CHAP. The CHAP must review prior
work on phthalates by the Commission,
but the Commission’s prior work is not
to be considered determinative. Within
180 days after completing its
examination, the CHAP shall report to
the Commission the results of the
examination and shall make
recommendations to the Commission
regarding any phthalates (or
combinations of phthalates or
alternatives to phthalates) in addition to
those permanently banned by the CPSIA
that the CHAP determines should be
declared hazardous substances.
The first meeting of the CHAP was on
April 14–15, 2010. The second meeting
of the CHAP will be on July 26–28,
2010, in the fourth floor hearing room
at the Commission’s offices in Bethesda,
MD (see address above). The CHAP is
seeking public comment on issues
relating to the hazard, exposure, and
risk posed by phthalates and phthalate
substitutes from all sources of exposure,
and especially in children’s products.
The CHAP is especially interested in
comments and data pertaining to:
1. Information on current and
anticipated future uses of phthalates
and phthalate substitutes in products,
including market data, production
levels, and the range of uses of specific
phthalates and phthalate substitutes in
different product types.
2. Data on the types and levels of
phthalates and phthalate substitutes
found in consumer products, cosmetics,
pharmaceutical drugs, medical devices,
food, food supplements, food packaging,
and pesticides.
3. Information on the relative
importance of different sources, routes,
E:\FR\FM\03JNN1.SGM
03JNN1
sroberts on DSKD5P82C1PROD with NOTICES
31428
Federal Register / Vol. 75, No. 106 / Thursday, June 3, 2010 / Notices
and pathways of exposure to phthalates
in the general population, expectant
mothers, and children. For example,
what are the relative contributions of
exposure from diet, consumer products,
ambient air, and other sources, which
may differ depending on the particular
phthalate and the exposed population?
4. Data on consumer use patterns
including the use of cosmetics and
consumer products that may contain
phthalates.
5. Data on children’s activity patterns,
including mouthing activity, exposure
to household dust, dermal exposure to
toys, and other potential child-specific
exposure pathways.
6. Information relating to human
exposure to phthalates and phthalate
substitutes, including migration data,
levels in environmental media (ambient
and indoor air, water, soil, household
dust), dermal exposure, oral exposure,
and bioavailability.
7. New, unpublished, or soon-to-be
published data on the types and levels
of phthalates, phthalate substitutes, or
their metabolites in human urine, blood,
milk, or other biological media.
8. Information relating to metabolism
or pharmacokinetic modeling that could
be used to estimate human exposure
from biomonitoring studies.
9. Toxicity data on the full range of
phthalates and phthalate substitutes in
commercial use, especially unpublished
or soon-to-be-published studies.
10. Human data on the toxicity of
phthalates, including epidemiological
and clinical studies, especially
unpublished or soon-to-be published
studies.
11. Information on the relative
sensitivity of potentially vulnerable
populations, including the fetus, young
children, and expectant mothers, and
whether there are any other vulnerable
populations that should be considered.
12. Information relating to assessing
the cumulative (combined) risk from
multiple phthalates, including dose
response data, methodology, which
health endpoint (or endpoints) is the
most relevant to human risk assessment,
and which phthalate substitutes or other
compounds may contribute to the
combined risk.
Any information submitted to CPSC
in response to this request will become
part of the public record. The CHAP is
especially interested in unpublished
studies relating to toxicity or exposure.
However, the CHAP will not consider
summaries of toxicological studies
prepared by chemical manufacturers as
substitutes for the complete studies.
There will be an opportunity for oral
comments on July 26, 2010, from 10
a.m. to 5 p.m. Persons wishing to
VerDate Mar<15>2010
18:21 Jun 02, 2010
Jkt 220001
present oral comments should file a
request with the Commission’s Office of
the Secretary no later than July 1, 2010,
and submit the text of their comments
not later than July 12, 2010.
Commenters should limit their
presentations to approximately 15
minutes, exclusive of any periods of
questioning by the members of the
CHAP or the CPSC staff. The CHAP may
further limit the time for any
presentation and to impose restrictions
to avoid excessive duplication of
presentations. Interested persons may
also file written comments with the
CHAP. Written comments must be filed
with the Office of the Secretary no later
than July 12, 2010. The remainder of the
CHAP meeting will be from 8:30 a.m. to
5 p.m. on July 27 and from 8:30 a.m. to
4 p.m. on July 28, 2010. During this part
of the meeting, the CHAP will discuss
issues and the report it will write.
Dated: May 28, 2010
Alberta E. Mills,
Acting Secretary, Consumer Product Safety
Commission.
[FR Doc. 2010–13389 Filed 6–2–10; 8:45 am]
BILLING CODE 6355–01–P
DEPARTMENT OF EDUCATION
Notice of Proposed Information
Collection Requests
Department of Education.
SUMMARY: The Acting Director,
Information Collection Clearance
Division, Regulatory Information
Management Services, Office of
Management, invites comments on the
proposed information collection
requests as required by the Paperwork
Reduction Act of 1995.
DATES: Interested persons are invited to
submit comments on or before August 2,
2010.
SUPPLEMENTARY INFORMATION: Section
3506 of the Paperwork Reduction Act of
1995 (44 U.S.C. Chapter 35) requires
that the Office of Management and
Budget (OMB) provide interested
Federal agencies and the public an early
opportunity to comment on information
collection requests. OMB may amend or
waive the requirement for public
consultation to the extent that public
participation in the approval process
would defeat the purpose of the
information collection, violate State or
Federal law, or substantially interfere
with any agency’s ability to perform its
statutory obligations. The Acting
Director, Information Collection
Clearance Division, Regulatory
Information Management Services,
Office of Management, publishes that
AGENCY:
PO 00000
Frm 00017
Fmt 4703
Sfmt 4703
notice containing proposed information
collection requests prior to submission
of these requests to OMB. Each
proposed information collection,
grouped by office, contains the
following: (1) Type of review requested,
e.g. new, revision, extension, existing or
reinstatement; (2) Title; (3) Summary of
the collection; (4) Description of the
need for, and proposed use of, the
information; (5) Respondents and
frequency of collection; and (6)
Reporting and/or Recordkeeping
burden. OMB invites public comment.
The Department of Education is
especially interested in public comment
addressing the following issues: (1) Is
this collection necessary to the proper
functions of the Department; (2) will
this information be processed and used
in a timely manner; (3) is the estimate
of burden accurate; (4) how might the
Department enhance the quality, utility,
and clarity of the information to be
collected; and (5) how might the
Department minimize the burden of this
collection on the respondents, including
through the use of information
technology.
Dated: May 28, 2010.
Sheila Carey,
Acting Director, Information Collection
Clearance Division, Regulatory Information
Management Services, Office of Management.
Office of Postsecondary Education
Type of Review: Revision.
Title: FIPSE Performance Reports.
Frequency: Annually.
Affected Public: Not-for-profit
institutions.
Reporting and Recordkeeping Hour
Burden:
Responses: 901.
Burden Hours: 10,426.
Abstract: This collection includes an
annual and a final performance report
for use with all of the following FIPSE
programs: Comprehensive (84.116B),
EU–U.S. (84.116J), U.S.-Brazil
(84.116M), North America (84.116N),
and U.S.-Russia (84.116S) Programs.
Also included is an annual and a final
performance report for CongressionallyDirected grants (earmarks) (84.116Z). A
total of five (5) forms comprise this
collection. We need to collect this data
in order to evaluate and assess each
grantee for continued funding and
assessment of their project.
Requests for copies of the proposed
information collection request may be
accessed from https://edicsweb.ed.gov,
by selecting the ‘‘Browse Pending
Collections’’ link and by clicking on link
number 4304. When you access the
information collection, click on
‘‘Download Attachments’’ to view.
E:\FR\FM\03JNN1.SGM
03JNN1
]]>Agencies
[Federal Register Volume 75, Number 106 (Thursday, June 3, 2010)]
[Notices]
[Pages 31426-31428]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-13389]
=======================================================================
-----------------------------------------------------------------------
CONSUMER PRODUCT SAFETY COMMISSION
Notice of Meeting of Chronic Hazard Advisory Panel on Phthalates
and Phthalate Substitutes and Opportunity for Public Comment
AGENCY: Consumer Product Safety Commission.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
[[Page 31427]]
SUMMARY: The Consumer Product Safety Commission (``CPSC'' or
``Commission'') announces the second meeting of the Chronic Hazard
Advisory Panel (CHAP) on phthalates and phthalate substitutes. The
Commission appointed this CHAP to study the effects on children's
health of all phthalates and phthalate alternatives as used in
children's toys and child care articles, pursuant to section 108 of the
Consumer Product Safety Improvement Act of 2008 (CPSIA) (Pub. L. 110-
314). The public may submit written or oral comments on the issues to
be considered by the CHAP.
DATES: The opportunity to present oral comments will be on July 26,
2010, from 10 a.m. to 5 p.m. The remainder of the meeting will be from
8:30 a.m. to 5 p.m. on July 27 and from 8:30 a.m. to 4 p.m. on July 28,
2010. Requests to present oral comments must be filed with the Office
of the Secretary no later than July 1, 2010. Written comments, and a
written copy of the text of the oral comments, must be received no
later than July 12, 2010. Commenters should limit their presentations
to approximately 15 minutes, exclusive of any periods of questioning by
the members of the CHAP or the Consumer Product Safety Commission
(CPSC) staff. The CHAP may further limit the time for any presentation
and to impose restrictions to avoid excessive duplication of
presentations.
ADDRESSES: The meeting will be in the fourth floor hearing room on July
26 and 27 and in room 410 on July 28, 2010, in the Commission's offices
at 4330 East West Highway, Bethesda, Maryland. Written comments, or
requests to present oral comments and the written text of such
comments, should be captioned ``CHAP on Phthalates'' and sent by
electronic mail (e-mail) to cpsc-os@cpsc.gov, or mailed or delivered to
the Office of the Secretary, Consumer Product Safety Commission, 4330
East-West Highway, Bethesda, Maryland 20814.
Online Registration and Webcast: Members of the public who wish to
attend the meeting are requested to preregister online at https://www.cpsc.gov/cgibin/chap.aspx. This meeting will also be available live
via webcast on July 26 and July 27, and by prerecorded webcast on July
28, 2010, at https://www.cpsc.gov/webcast. Registration is not necessary
to view the webcast.
FOR FURTHER INFORMATION CONTACT: Concerning requests and procedures for
oral presentations of comments: Rockelle Hammond, Consumer Product
Safety Commission, Bethesda, MD 20814; telephone: (301) 504-6833; e-
mail cpscos@cpsc.gov. For all other matters: Michael Babich,
Directorate for Health Sciences, Consumer Product Safety Commission,
Bethesda, MD 20814; telephone (301) 504-07253; e-mail mbabich@cpsc.gov.
SUPPLEMENTARY INFORMATION: The Commission has previously investigated
potential risks posed to children from phthalate plasticizers,
especially di (2-ethylhexyl) phthalate (DEHP) and diisononyl phthalate
(DINP), which were used to soften some children's teethers, rattles,
and toys made from polyvinyl chloride (PVC). Phthalates can leach from
such products when they are mouthed by children, causing some
phthalates to be ingested. In addition, children and adults can be
exposed to phthalates from many sources, including consumer products,
food, cosmetics, medical devices, and the environment. Certain
phthalates have been shown to cause adverse health effects, including
birth defects, in laboratory animals. Section 108 of the CPSIA
permanently prohibits the sale of any ``children's toy or child care
article'' containing more than 0.1 percent of each of three specified
phthalates--di-(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate
(DBP), and benzyl butyl phthalate (BBP). Section 108 of the CPSIA also
prohibits on an interim basis the sale of any ``children's toy that can
be placed in a child's mouth'' or ``child care articles'' containing
more than 0.1 percent of each of three additional phthalates--
diisononyl phthalate (DINP), diisodecyl phthalate (DIDP), and di-n-
octyl phthalate (DnOP).
Section 108 of the CPSIA requires the Commission to convene a CHAP
``to study the effects on children's health of all phthalates and
phthalate alternatives as used in children's toys and child care
articles.'' The CPSIA requires the CHAP to complete an examination of
the full range of phthalates that are used in products for children and
to: (i) Examine all of the potential health effects (including
endocrine disrupting effects) of the full range of phthalates; (ii)
consider the potential health effects of each of these phthalates both
in isolation and in combination with other phthalates; (iii) examine
the likely levels of children's, pregnant women's, and others' exposure
to phthalates, based on a reasonable estimation of normal and
foreseeable use and abuse of such products; (iv) consider the
cumulative effect of total exposure to phthalates, both from children's
products and from other sources, such as personal care products; (v)
review all relevant data, including the most recent, best-available,
peer-reviewed, scientific studies of these phthalates and phthalate
alternatives that employ objective data collection practices or employ
other objective methods; (vi) consider the health effects of phthalates
not only from ingestion but also as a result of dermal, hand-to-mouth,
or other exposure; (vii) consider the level at which there is a
reasonable certainty of no harm to children, pregnant women, or other
susceptible individuals and their offspring, considering the best
available science, and using sufficient safety factors to account for
uncertainties regarding exposure and susceptibility of children,
pregnant women, and other potentially susceptible individuals; and
(viii) consider possible similar health effects of phthalate
alternatives used in children's toys and child care articles.
The CHAP's examination must be conducted de novo, and the statute
specifies completion of its examination within 18 months of appointment
of the CHAP. The CHAP must review prior work on phthalates by the
Commission, but the Commission's prior work is not to be considered
determinative. Within 180 days after completing its examination, the
CHAP shall report to the Commission the results of the examination and
shall make recommendations to the Commission regarding any phthalates
(or combinations of phthalates or alternatives to phthalates) in
addition to those permanently banned by the CPSIA that the CHAP
determines should be declared hazardous substances.
The first meeting of the CHAP was on April 14-15, 2010. The second
meeting of the CHAP will be on July 26-28, 2010, in the fourth floor
hearing room at the Commission's offices in Bethesda, MD (see address
above). The CHAP is seeking public comment on issues relating to the
hazard, exposure, and risk posed by phthalates and phthalate
substitutes from all sources of exposure, and especially in children's
products. The CHAP is especially interested in comments and data
pertaining to:
1. Information on current and anticipated future uses of phthalates
and phthalate substitutes in products, including market data,
production levels, and the range of uses of specific phthalates and
phthalate substitutes in different product types.
2. Data on the types and levels of phthalates and phthalate
substitutes found in consumer products, cosmetics, pharmaceutical
drugs, medical devices, food, food supplements, food packaging, and
pesticides.
3. Information on the relative importance of different sources,
routes,
[[Page 31428]]
and pathways of exposure to phthalates in the general population,
expectant mothers, and children. For example, what are the relative
contributions of exposure from diet, consumer products, ambient air,
and other sources, which may differ depending on the particular
phthalate and the exposed population?
4. Data on consumer use patterns including the use of cosmetics and
consumer products that may contain phthalates.
5. Data on children's activity patterns, including mouthing
activity, exposure to household dust, dermal exposure to toys, and
other potential child-specific exposure pathways.
6. Information relating to human exposure to phthalates and
phthalate substitutes, including migration data, levels in
environmental media (ambient and indoor air, water, soil, household
dust), dermal exposure, oral exposure, and bioavailability.
7. New, unpublished, or soon-to-be published data on the types and
levels of phthalates, phthalate substitutes, or their metabolites in
human urine, blood, milk, or other biological media.
8. Information relating to metabolism or pharmacokinetic modeling
that could be used to estimate human exposure from biomonitoring
studies.
9. Toxicity data on the full range of phthalates and phthalate
substitutes in commercial use, especially unpublished or soon-to-be-
published studies.
10. Human data on the toxicity of phthalates, including
epidemiological and clinical studies, especially unpublished or soon-
to-be published studies.
11. Information on the relative sensitivity of potentially
vulnerable populations, including the fetus, young children, and
expectant mothers, and whether there are any other vulnerable
populations that should be considered.
12. Information relating to assessing the cumulative (combined)
risk from multiple phthalates, including dose response data,
methodology, which health endpoint (or endpoints) is the most relevant
to human risk assessment, and which phthalate substitutes or other
compounds may contribute to the combined risk.
Any information submitted to CPSC in response to this request will
become part of the public record. The CHAP is especially interested in
unpublished studies relating to toxicity or exposure. However, the CHAP
will not consider summaries of toxicological studies prepared by
chemical manufacturers as substitutes for the complete studies.
There will be an opportunity for oral comments on July 26, 2010,
from 10 a.m. to 5 p.m. Persons wishing to present oral comments should
file a request with the Commission's Office of the Secretary no later
than July 1, 2010, and submit the text of their comments not later than
July 12, 2010. Commenters should limit their presentations to
approximately 15 minutes, exclusive of any periods of questioning by
the members of the CHAP or the CPSC staff. The CHAP may further limit
the time for any presentation and to impose restrictions to avoid
excessive duplication of presentations. Interested persons may also
file written comments with the CHAP. Written comments must be filed
with the Office of the Secretary no later than July 12, 2010. The
remainder of the CHAP meeting will be from 8:30 a.m. to 5 p.m. on July
27 and from 8:30 a.m. to 4 p.m. on July 28, 2010. During this part of
the meeting, the CHAP will discuss issues and the report it will write.
Dated: May 28, 2010
Alberta E. Mills,
Acting Secretary, Consumer Product Safety Commission.
[FR Doc. 2010-13389 Filed 6-2-10; 8:45 am]
BILLING CODE 6355-01-P
